| Pipeline |
|
EGEN is actively engaged in development and discovery research. Our most advanced product is currently being clinically evaluated as a cancer immunotherapy. Several other projects directed towards cardiovascular anomalies and diseases of the joint tissue are at the research stage. Additionally, EGEN has developed commercially available research reagents (Arrest-In™) that are marketed through a corporate partner (Thermo Fisher Scientific Open Biosystems products).
|
| < Prev | Next > |
|---|